Literature DB >> 20498440

Diffuse low-grade oligodendrogliomas extend beyond MRI-defined abnormalities.

J Pallud1, P Varlet, B Devaux, S Geha, M Badoual, C Deroulers, P Page, E Dezamis, C Daumas-Duport, F-X Roux.   

Abstract

BACKGROUND: Imaging determinations of the spatial extent of diffuse low-grade gliomas (DLGGs) are of paramount importance in evaluating the risk-to-benefit ratio of surgical resection. However, it is not clear how accurately preoperative conventional MRI can delineate DLGGs.
METHODS: We report a retrospective histologic and imaging correlation study in 16 adult patients who underwent serial stereotactic biopsies for the diagnosis of untreated supratentorial well-defined and non-contrast-enhanced DLGG, in whom biopsy samples were taken within and beyond (OutBSs) MRI-defined abnormalities.
RESULTS: Thirty-seven OutBSs that extended from 10 to 26 mm beyond MRI-defined abnormalities were studied. Immunostaining revealed MIB-1-positive cells (i.e., cycling cells) in all but 2 of the OutBSs. None of the MIB-1-positive cells coexpressed glial fibrillary acidic protein, and all of them coexpressed OLIG2. MIB-1-positive cells were cycling isolated tumor cells, because 1) their morphologic characteristics reflected those of tumor cells, 2) the number of MIB-1-positive cells per square centimeter was significantly higher than that of controls, 3) the number of MIB-1-positive cells per square centimeter was positively correlated with the tumor growth fraction (p = 0.012), and 4) the number of MIB-1-positive cells per square centimeter in OutBSs decreased with distance from the tumor (p = 0.003).
CONCLUSIONS: This study demonstrates, using a multiscale correlative approach, that conventional MRI underestimates the actual spatial extent of diffuse low-grade gliomas (DLGGs), even when they are well delineated. These results suggest that an extended resection of a margin beyond MRI-defined abnormalities, whenever feasible in noneloquent brain areas, might improve the outcome of DLGGs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20498440     DOI: 10.1212/WNL.0b013e3181e04264

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  54 in total

1.  Improving the time-machine: estimating date of birth of grade II gliomas.

Authors:  C Gerin; J Pallud; B Grammaticos; E Mandonnet; C Deroulers; P Varlet; L Capelle; L Taillandier; L Bauchet; H Duffau; M Badoual
Journal:  Cell Prolif       Date:  2011-12-14       Impact factor: 6.831

2.  Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas.

Authors:  Johan Pallud; Jean-François Llitjos; Frédéric Dhermain; Pascale Varlet; Edouard Dezamis; Bertrand Devaux; Raphaëlle Souillard-Scémama; Nader Sanai; Maria Koziak; Philippe Page; Michel Schlienger; Catherine Daumas-Duport; Jean-François Meder; Catherine Oppenheim; François-Xavier Roux
Journal:  Neuro Oncol       Date:  2012-03-13       Impact factor: 12.300

3.  Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas.

Authors:  Johan Pallud; Marie Blonski; Emmanuel Mandonnet; Etienne Audureau; Denys Fontaine; Nader Sanai; Luc Bauchet; Philippe Peruzzi; Marc Frénay; Philippe Colin; Rémy Guillevin; Valérie Bernier; Marie-Hélène Baron; Jacques Guyotat; Hugues Duffau; Luc Taillandier; Laurent Capelle
Journal:  Neuro Oncol       Date:  2013-02-07       Impact factor: 12.300

Review 4.  'Low grade glioma': an update for radiologists.

Authors:  Jennifer Larsen; Steve B Wharton; Fiona McKevitt; Charles Romanowski; Caroline Bridgewater; Hesham Zaki; Nigel Hoggard
Journal:  Br J Radiol       Date:  2016-12-07       Impact factor: 3.039

Review 5.  The role of surgery in grade II/III oligodendroglial tumors.

Authors:  Niklas Thon; Friedrich-Wilhelm Kreth; Joerg-Christian Tonn
Journal:  CNS Oncol       Date:  2015-10-19

6.  Is a prospective trial necessary to suggest a clinical relevance?

Authors:  Johan Pallud; Hugues Duffau
Journal:  Neuro Oncol       Date:  2014-08-05       Impact factor: 12.300

7.  Brain tumors in eloquent areas: A European multicenter survey of intraoperative mapping techniques, intraoperative seizures occurrence, and antiepileptic drug prophylaxis.

Authors:  Giannantonio Spena; Philippe Schucht; Kathleen Seidel; Geert-Jan Rutten; Christian Franz Freyschlag; Federico D'Agata; Emanule Costi; Francesca Zappa; Marco Fontanella; Denys Fontaine; Fabien Almairac; Michele Cavallo; Pasquale De Bonis; Gerardo Conesa; Nicholas Foroglou; Santiago Gil-Robles; Emanuel Mandonnet; Juan Martino; Thomas Picht; Catarina Viegas; Michel Wager; Johan Pallud
Journal:  Neurosurg Rev       Date:  2016-08-01       Impact factor: 3.042

8.  Label-Free Neurosurgical Pathology with Stimulated Raman Imaging.

Authors:  Fa-Ke Lu; David Calligaris; Olutayo I Olubiyi; Isaiah Norton; Wenlong Yang; Sandro Santagata; X Sunney Xie; Alexandra J Golby; Nathalie Y R Agar
Journal:  Cancer Res       Date:  2016-04-12       Impact factor: 12.701

Review 9.  Incidental diffuse low-grade gliomas: from early detection to preventive neuro-oncological surgery.

Authors:  Guilherme Lucas de Oliveira Lima; Marc Zanello; Emmanuel Mandonnet; Luc Taillandier; Johan Pallud; Hugues Duffau
Journal:  Neurosurg Rev       Date:  2015-11-27       Impact factor: 3.042

10.  Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients.

Authors:  Marie Blonski; Johan Pallud; Catherine Gozé; Emmanuel Mandonnet; Valérie Rigau; Luc Bauchet; Michel Fabbro; Patrick Beauchesne; Marie-Hélène Baron; Denys Fontaine; Philippe Peruzzi; Amélie Darlix; Hugues Duffau; Luc Taillandier
Journal:  J Neurooncol       Date:  2013-03-12       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.